Related Experiment Video
Updated: Jul 7, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Long-term Parkinson's disease--time for optimism.
Shlomit Yust-Katz1, Sonia Sthneer, Eldad Melamed
1Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel. liorshlomit@yahoo.com
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|February 26, 2008
Summary
Parkinson's disease (PD) is a chronic, progressive condition. While levodopa treatment initially helps most patients, its effectiveness diminishes over time, and many reach advanced stages of disability.
Area of Science:
- Neurology
- Neuroscience
- Clinical Research
Background:
- Long-term natural history data for Parkinson's disease (PD) are limited.
- Understanding disease progression and treatment response is crucial for patient management.
Purpose of the Study:
- To describe the long-term evolution of functional disability in Parkinson's disease.
- To assess the sustained response to dopaminergic therapy in patients with established PD.
Main Methods:
- Retrospective review of medical records for 47 patients diagnosed with PD over 13 years prior.
- Analysis of disease duration, age at onset, Hoehn and Yahr (H&Y) staging, and response to levodopa.
- Comparison of H&Y stages between patients with and without motor fluctuations.
Main Results:
- Initial levodopa effectiveness was observed in 95% of patients, with response waning over time.
- At follow-up, 45% of patients reached Hoehn and Yahr stage 5 (end-stage disease).
- Patients with motor fluctuations showed higher rates of end-stage disease (53% in 'off' vs. 27% in 'on' periods) compared to those without (23%).
Conclusions:
- Parkinson's disease follows a chronic, progressive course, though not all patients reach end-stage.
- The efficacy of levodopa decreases over the long term but remains present.
- Motor fluctuations significantly impact disability levels in advanced Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...